Clinical Trial Update: Viekira Pak or Mavyret Treatment for Patient With Chronic Kidney Disease and Hepatitis C [Phase 4]

View source ↗

Summary

Phase 4 trial updating outcomes of Viekira Pak or Mavyret in patients with chronic kidney disease and chronic hepatitis C; completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Hepatitis C

Drugs mentioned

• Mavyret (glecaprevir/pibrentasvir)
• Viekira Pak (glecaprevir/pibrentasvir or ombitasvir/paritaprevir/ritonavir/dasabuvir)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Chronic Kidney Disease, Chronic Hepatitis C | Phase 4 | Status: COMPLETED | Results posted: 2021-11-05